Physician profile
Ashlea Feezel
NPI 1306343256
$3,875.37
in general payments reported to CMS, 2019-2025
32 companies · $1,488 in 2025
The $1,488 reported for 2025 was more than what 75% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.67 · 2023: $547 · 2024: $1,816 · 2025: $1,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,797 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,796.71 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $497.99 | 2023-2025 | Fintepla, Nayzilam, Briviact |
| Corium, LLC | $325.45 | 2023-2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $314.04 | 2023-2025 | Xywav, Epidiolex |
| Neurelis, INC. | $303.69 | 2023-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $296.82 | 2023-2025 | Qelbree, Qelbree |
| Avadel Cns Pharmaceuticals, LLC | $283.47 | 2023-2025 | Lumryz |
| Ironshore Pharmaceuticals INC. | $264.97 | 2024 | |
| Sumitomo Pharma America, INC. | $216.40 | 2024 | Aptiom |
| Octapharma USA, INC. | $139.24 | 2023-2025 | Panzyga |
| Sk Life Science, INC. | $134.04 | 2023-2025 | |
| Harmony Biosciences LLC | $115.87 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $110.73 | 2024 | |
| Livanova USA, INC. | $102.07 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Tempus Ai, INC | $94.56 | 2024-2025 | Tempus Pixel, Tempus Pixel |
| Abbvie INC. | $78.46 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $68.02 | 2025 | Jornay Pm |
| Otter Pharmaceuticals, LLC | $59.90 | 2024-2025 | Sympazan |
| Vertical Pharmaceuticals, LLC | $56.67 | 2024-2025 | Relexxii |
| Acadia Pharmaceuticals INC | $45.08 | 2023-2024 | Daybue |
| Springworks Therapeutics, INC. | $44.91 | 2025 | Gomekli |
| Aquestive Therapeutics, INC. | $44.11 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $34.08 | 2024 | Dysport |
| Janssen Biotech, INC. | $31.30 | 2025 | |
| Immedica Pharma US, INC. | $28.36 | 2023 | |
| Tris Pharma INC | $26.25 | 2025 | Onyda Xr |
| Hospira, INC. | $25.49 | 2025 | |
| Biogen, INC. | $24.77 | 2025 | Skyclarys |
| Axsome Therapeutics, INC. | $23.83 | 2025 | Symbravo |
| Intrabio INC | $18.70 | 2025 | Aqneursa |
| Noven Therapeutics, LLC | $16.53 | 2025 | Xelstrym |
| Owp Pharmaceuticals, INC. | $14.39 | 2025 | Subvenite |
| Aucta Pharmaceuticals, INC. | $11.51 | 2024 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlea Feezel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.